The safety and efficacy of the combination of Sacituzumab Govitecan and palliative radiotherapy: a retrospective multi-center cohort study
Sacituzumab govitecan (SG) is a new treatment option for patients with metastatic triple-negative and hormone receptor-positive, HER2-negative breast cancer. This antibody-drug conjugate is currently approved as monotherapy. Palliative radiotherapy is frequently used to treat symptomatic metastases...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
25 April 2024
|
| In: |
Cancers
Year: 2024, Volume: 16, Issue: 9, Pages: 1649-1-1649-12 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers16091649 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers16091649 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/16/9/1649 
|
| Author Notes: | David Krug, Joke Tio, Ali Abaci, Björn Beurer, Sandra Brügge, Khaled Elsayad, Eva Meixner, Tjoung-Won Park-Simon, Katharina Smetanay, Franziska Winkelmann, Andrea Wittig and Achim Wöckel |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 190875818X | ||
| 003 | DE-627 | ||
| 005 | 20241205220717.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 241115s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers16091649 |2 doi | |
| 035 | |a (DE-627)190875818X | ||
| 035 | |a (DE-599)KXP190875818X | ||
| 035 | |a (OCoLC)1475647332 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Krug, David |e VerfasserIn |0 (DE-588)1062940202 |0 (DE-627)807054747 |0 (DE-576)420297944 |4 aut | |
| 245 | 1 | 4 | |a The safety and efficacy of the combination of Sacituzumab Govitecan and palliative radiotherapy |b a retrospective multi-center cohort study |c David Krug, Joke Tio, Ali Abaci, Björn Beurer, Sandra Brügge, Khaled Elsayad, Eva Meixner, Tjoung-Won Park-Simon, Katharina Smetanay, Franziska Winkelmann, Andrea Wittig and Achim Wöckel |
| 264 | 1 | |c 25 April 2024 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 14.11.2024 | ||
| 520 | |a Sacituzumab govitecan (SG) is a new treatment option for patients with metastatic triple-negative and hormone receptor-positive, HER2-negative breast cancer. This antibody-drug conjugate is currently approved as monotherapy. Palliative radiotherapy is frequently used to treat symptomatic metastases locally. Concurrent use of SG and irradiation was excluded in clinical trials of SG, and there are currently limited published data. We report here a systematic review, as well as a retrospective multi-center study of 17 patients with triple-negative breast cancer who received concurrent SG and radiotherapy. In these patients, concurrent use was found to be efficient, safe and well tolerated. There were no apparent differences in moderate or severe acute toxicity according to the timing of SG administration. | ||
| 650 | 4 | |a antibody-drug conjugate | |
| 650 | 4 | |a brain metastases | |
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a palliative radiotherapy | |
| 650 | 4 | |a radiosurgery | |
| 650 | 4 | |a stereotactic radiotherapy | |
| 700 | 1 | |a Tio, Joke |d 1971- |e VerfasserIn |0 (DE-588)124410359 |0 (DE-627)363327762 |0 (DE-576)294159061 |4 aut | |
| 700 | 1 | |a Abaci, Ali |d 1979- |e VerfasserIn |0 (DE-588)1070672920 |0 (DE-627)824435346 |0 (DE-576)432195297 |4 aut | |
| 700 | 1 | |a Beurer, Björn Michael |d 1978- |e VerfasserIn |0 (DE-588)1026434165 |0 (DE-627)726721271 |0 (DE-576)371773032 |4 aut | |
| 700 | 1 | |a Brügge, Sandra |e VerfasserIn |4 aut | |
| 700 | 1 | |a Elsayad, Khaled |d 1984- |e VerfasserIn |0 (DE-588)1095566334 |0 (DE-627)856199168 |0 (DE-576)464856825 |4 aut | |
| 700 | 1 | |a Meixner, Eva |e VerfasserIn |0 (DE-588)1222706334 |0 (DE-627)174193141X |4 aut | |
| 700 | 1 | |a Park-Simon, Tjoung-Won |e VerfasserIn |0 (DE-588)1102938580 |0 (DE-627)860528898 |0 (DE-576)470356332 |4 aut | |
| 700 | 1 | |a Smetanay, Katharina |d 1982- |e VerfasserIn |0 (DE-588)140122036 |0 (DE-627)616034857 |0 (DE-576)314686452 |4 aut | |
| 700 | 1 | |a Winkelmann, Franziska |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wittig-Sauerwein, Andrea |d 1971- |e VerfasserIn |0 (DE-588)1283461005 |0 (DE-627)1839225521 |4 aut | |
| 700 | 1 | |a Wöckel, Achim |d 1975- |e VerfasserIn |0 (DE-588)124691307 |0 (DE-627)364365838 |0 (DE-576)294450718 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d Basel : MDPI, 2009 |g 16(2024), 9, Artikel-ID 1649, Seite 1649-1-1649-12 |h Online-Ressource |w (DE-627)614095670 |w (DE-600)2527080-1 |w (DE-576)313958548 |x 2072-6694 |7 nnas |a The safety and efficacy of the combination of Sacituzumab Govitecan and palliative radiotherapy a retrospective multi-center cohort study |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g number:9 |g elocationid:1649 |g pages:1649-1-1649-12 |g extent:12 |a The safety and efficacy of the combination of Sacituzumab Govitecan and palliative radiotherapy a retrospective multi-center cohort study |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cancers16091649 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2072-6694/16/9/1649 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20241115 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 140122036 |a Smetanay, Katharina |m 140122036:Smetanay, Katharina |d 910000 |d 910400 |e 910000PS140122036 |e 910400PS140122036 |k 0/910000/ |k 1/910000/910400/ |p 9 | ||
| 998 | |g 1222706334 |a Meixner, Eva |m 1222706334:Meixner, Eva |d 910000 |d 911400 |d 50000 |e 910000PM1222706334 |e 911400PM1222706334 |e 50000PM1222706334 |k 0/910000/ |k 1/910000/911400/ |k 0/50000/ |p 7 | ||
| 999 | |a KXP-PPN190875818X |e 4615261608 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"given":"David","display":"Krug, David","role":"aut","family":"Krug"},{"given":"Joke","display":"Tio, Joke","role":"aut","family":"Tio"},{"given":"Ali","display":"Abaci, Ali","family":"Abaci","role":"aut"},{"role":"aut","family":"Beurer","given":"Björn Michael","display":"Beurer, Björn Michael"},{"role":"aut","family":"Brügge","display":"Brügge, Sandra","given":"Sandra"},{"given":"Khaled","display":"Elsayad, Khaled","role":"aut","family":"Elsayad"},{"given":"Eva","display":"Meixner, Eva","family":"Meixner","role":"aut"},{"family":"Park-Simon","role":"aut","given":"Tjoung-Won","display":"Park-Simon, Tjoung-Won"},{"given":"Katharina","display":"Smetanay, Katharina","family":"Smetanay","role":"aut"},{"given":"Franziska","display":"Winkelmann, Franziska","role":"aut","family":"Winkelmann"},{"role":"aut","family":"Wittig-Sauerwein","given":"Andrea","display":"Wittig-Sauerwein, Andrea"},{"family":"Wöckel","role":"aut","given":"Achim","display":"Wöckel, Achim"}],"recId":"190875818X","note":["Gesehen am 14.11.2024"],"name":{"displayForm":["David Krug, Joke Tio, Ali Abaci, Björn Beurer, Sandra Brügge, Khaled Elsayad, Eva Meixner, Tjoung-Won Park-Simon, Katharina Smetanay, Franziska Winkelmann, Andrea Wittig and Achim Wöckel"]},"language":["eng"],"relHost":[{"language":["eng"],"part":{"year":"2024","volume":"16","text":"16(2024), 9, Artikel-ID 1649, Seite 1649-1-1649-12","pages":"1649-1-1649-12","extent":"12","issue":"9"},"pubHistory":["1.2009 -"],"note":["Gesehen am 27.05.2020"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"The safety and efficacy of the combination of Sacituzumab Govitecan and palliative radiotherapy a retrospective multi-center cohort studyCancers","name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]},"recId":"614095670","title":[{"title":"Cancers","title_sort":"Cancers"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2527080-1"],"eki":["614095670"],"issn":["2072-6694"]},"origin":[{"publisher":"MDPI","dateIssuedDisp":"2009-","dateIssuedKey":"2009","publisherPlace":"Basel"}]}],"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"25 April 2024"}],"title":[{"title":"The safety and efficacy of the combination of Sacituzumab Govitecan and palliative radiotherapy","subtitle":"a retrospective multi-center cohort study","title_sort":"safety and efficacy of the combination of Sacituzumab Govitecan and palliative radiotherapy"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["190875818X"],"doi":["10.3390/cancers16091649"]},"physDesc":[{"extent":"12 S."}]} | ||
| SRT | |a KRUGDAVIDTSAFETYANDE2520 | ||